These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 36225133)
21. Examining the Interplay Between Preexposure Prophylaxis (PrEP) and Gender-Related Stigmas as Barriers for PrEP Uptake Among Transgender Women in Tijuana, Mexico: A Mixed-Methods Study. Algarin AB; Cirilo A; Pitpitan EV; Pines HA; Padilla-Garcia R; Zapien-Vasquez MF; Navarro-Alvarez S; Smith LR AIDS Behav; 2024 Nov; 28(11):3655-3665. PubMed ID: 39080200 [TBL] [Abstract][Full Text] [Related]
22. Programme science in action: lessons from an observational study of HIV prevention programming for key populations in Lusaka, Zambia. Sikazwe I; Musheke M; Chiyenu K; Ngosa B; Pry JM; Mulubwa C; Zimba M; Sakala M; Sakala M; Somwe P; Nyirenda G; Savory T; Bolton-Moore C; Herce ME J Int AIDS Soc; 2024 Jul; 27 Suppl 2(Suppl 2):e26237. PubMed ID: 38982890 [TBL] [Abstract][Full Text] [Related]
23. Barriers and facilitators to pre-exposure prophylaxis uptake among male sex workers in Mexico: an application of the RE-AIM framework. Kadiamada-Ibarra H; Hawley NL; Sosa-Rubí SG; Wilson-Barthes M; Franco RR; Galárraga O BMC Public Health; 2021 Nov; 21(1):2174. PubMed ID: 34837988 [TBL] [Abstract][Full Text] [Related]
24. Characteristics Associated with Pre-Exposure Prophylaxis Discussion and Use Among Transgender Women Without HIV Infection - National HIV Behavioral Surveillance Among Transgender Women, Seven Urban Areas, United States, 2019-2020. Morris E; Teplinskaya A; Olansky E; Rinderle JK; Chapin-Bardales J; MMWR Suppl; 2024 Jan; 73(1):9-20. PubMed ID: 38261546 [TBL] [Abstract][Full Text] [Related]
25. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. Yager JL; Anderson PL Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):463-474. PubMed ID: 32250177 [TBL] [Abstract][Full Text] [Related]
26. A Promising PrEP Navigation Intervention for Transgender Women and Men Who Have Sex with Men Experiencing Multiple Syndemic Health Disparities. Reback CJ; Clark KA; Rünger D; Fehrenbacher AE J Community Health; 2019 Dec; 44(6):1193-1203. PubMed ID: 31317438 [TBL] [Abstract][Full Text] [Related]
27. Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California. Watson CW; Pasipanodya E; Savin MJ; Ellorin EE; Corado KC; Flynn RP; Opalo C; Lampley E; Henry BL; Blumenthal J; Bolan R; Morris S; Moore DJ AIDS Educ Prev; 2020 Dec; 32(6):472-485. PubMed ID: 33779208 [TBL] [Abstract][Full Text] [Related]
28. Pre-exposure prophylaxis for transgender women and men who have sex with men: qualitative insights from healthcare providers, community organization-based leadership and end users in coastal Kenya. Kimani M; Sanders EJ; Chirro O; Mukuria N; Mahmoud S; Rinke de Wit TF; Graham SM; Operario D; van der Elst EM Int Health; 2022 May; 14(3):288-294. PubMed ID: 34325469 [TBL] [Abstract][Full Text] [Related]
29. Acceptability of HIV Pre-Exposure Prophylaxis Among Transgender Women in India: A Qualitative Investigation. Chakrapani V; Shunmugam M; Rawat S; Baruah D; Nelson R; Newman PA AIDS Patient Care STDS; 2020 Feb; 34(2):92-98. PubMed ID: 31951490 [TBL] [Abstract][Full Text] [Related]
30. Increasing Access to Pre-Exposure Prophylaxis Among Transgender Women and Transfeminine Nonbinary Individuals. Klein A; Golub SA AIDS Patient Care STDS; 2019 Jun; 33(6):262-269. PubMed ID: 31166785 [TBL] [Abstract][Full Text] [Related]
31. HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals. Poteat TC; Radix A Drugs; 2020 Jul; 80(10):965-972. PubMed ID: 32451925 [TBL] [Abstract][Full Text] [Related]
32. Mapping Community-Engaged Implementation Strategies with Transgender Scientists, Stakeholders, and Trans-Led Community Organizations. Restar A; Minalga BJ; Quilantang MI; Adamson T; Dusic E; van der Merwe LA; Millet G; Rosadiño D; Laguing T; Lett E; Everhart A; Phillips G; Janamnuaysook R; Seekaew P; Baker K; Ashley F; Wickersham J; Wallace SE; Operario D; Gamarel KE Curr HIV/AIDS Rep; 2023 Jun; 20(3):160-169. PubMed ID: 37012537 [TBL] [Abstract][Full Text] [Related]
33. Exploring the Association Between Gender Affirmation and PrEP use Among Transgender Women in New York City. Rivera AV; Lopez JM; Braunstein SL AIDS Behav; 2023 May; 27(5):1523-1530. PubMed ID: 36574185 [TBL] [Abstract][Full Text] [Related]
34. Intention to Use Different Formulations of Longer Acting HIV Pre-Exposure Prophylaxis Among Transgender and Gender Expansive Individuals: The Roles of Social Vulnerability and Medical Mistrust. Schnarrs PW; Zuñiga J; Benitez G; Fliedner P; Norwood A; Croll M; Oviedo LDS; Buchorn J; Oeffinger J; Lane R; Schelling E; Pham G; Pate T; Arnold EM AIDS Patient Care STDS; 2024 Feb; 38(2):51-60. PubMed ID: 38381948 [TBL] [Abstract][Full Text] [Related]
35. Transgender Women's Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs). Rael CT; Martinez M; Giguere R; Bockting W; MacCrate C; Mellman W; Valente P; Greene GJ; Sherman SG; Footer KHA; D'Aquila RT; Carballo-Diéguez A; Hope TJ AIDS Behav; 2020 May; 24(5):1452-1462. PubMed ID: 31654172 [TBL] [Abstract][Full Text] [Related]
36. Barriers to the uptake of oral pre-exposure prophylaxis among young key populations in Nigeria. Olakunde BO; Ujam C; Ndukwe CD; Falola-Anoemuah Y; Olaifa Y; Oladele TT; Yahaya HB; Ogundipe A Int J STD AIDS; 2024 Apr; 35(5):346-351. PubMed ID: 38105179 [TBL] [Abstract][Full Text] [Related]
37. Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California. Sevelius JM; Glidden DV; Deutsch M; Welborn L; Contreras A; Salinas A; Venegas L; Grant RM J Acquir Immune Defic Syndr; 2021 Dec; 88(S1):S27-S38. PubMed ID: 34757990 [TBL] [Abstract][Full Text] [Related]
38. PrEP initiation and discontinuation among transgender women in the United States: a longitudinal, mixed methods cohort study. Cooney EE; Saleem HT; Stevenson M; Aguayo-Romero RA; Althoff KN; Poteat TC; Beckham SW; Adams D; Radix AE; Wawrzyniak AJ; Cannon CM; Schneider JS; Haw JS; Rodriguez AE; Mayer KH; Beyrer C; Reisner SL; Wirtz AL; J Int AIDS Soc; 2023 Dec; 26(12):e26199. PubMed ID: 38123897 [TBL] [Abstract][Full Text] [Related]
39. Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. Grant RM; Sevelius JM; Guanira JV; Aguilar JV; Chariyalertsak S; Deutsch MB J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 3(Suppl 3):S226-9. PubMed ID: 27429187 [TBL] [Abstract][Full Text] [Related]
40. Facilitators of PrEP Persistence among Black and Latinx Transgender Women in a PrEP Demonstration Project in Southern California. Storholm ED; Ogunbajo A; Nacht CL; Opalo C; Horvath KJ; Lyman P; Flynn R; Reback CJ; Blumenthal J; Moore DJ; Bolan R; Morris S Behav Med; 2024; 50(1):63-74. PubMed ID: 35993278 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]